BioNeex Logo

Blog

Interview with Dr. John L. LaMattina, former R&D President of Pfizer

Sep 04, 2018

How do you decide on whether to advance or not New Molecular Entities (NMEs)? What happens to abandoned compounds? Is there such a thing as “death compound acquisition or licensing”? […]

read more